An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.

about

An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.

Item

http://www.wikidata.org/entity/Q38869809

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

An Unusual Case of Central Ret ...... Regorafenib in GIST Patients.

@en

type

Item

label

An Unusual Case of Central Ret ...... Regorafenib in GIST Patients.

@en

prefLabel

An Unusual Case of Central Ret ...... Regorafenib in GIST Patients.

@en

P1476

An Unusual Case of Central Ret ...... f Regorafenib in GIST Patients

@en

P2093

Chrystia M Zobniw

http://www.w3.org/2001/XMLSchema#string

Michael J Wagner

http://www.w3.org/2001/XMLSchema#string

Neeta Somaiah

http://www.w3.org/2001/XMLSchema#string

Shreyaskumar Patel

http://www.w3.org/2001/XMLSchema#string

Van Anh Trinh

http://www.w3.org/2001/XMLSchema#string

P2860

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

PDGFRA activating mutations in gastrointestinal stromal tumors.

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

P2888

s11912-016-0536-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-016-0536-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gustavo Schvartsman

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014472126

http://www.w3.org/2001/XMLSchema#string

P698

27319943

http://www.w3.org/2001/XMLSchema#string